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1872	 IS	 and	 TIA	 survivors	 admitted	 to	 the	 stroke	 unit	 at	 Haukeland	 University	
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1  | INTRODUC TION
The	 incidences	 of	 stroke	 and	 post‐stroke	mortality	 have	 declined	
heavily	 in	 high‐income	 countries	 in	 the	 last	 50	years,	 mainly	 be‐
cause	of	 changes	 in	 cardiovascular	 risk	 factors	 and	 improvements	
in	acute	stroke	 treatment.1	Despite	progress	and	declining	 trends,	
recurrent	 stroke	 is	 still	 frequent.2,3	 Studies	 demonstrate	 varying	
recurrence	 rates,	 ranging	 from	 7%‐20%	 at	 1	year	 to	 16%‐35%	 at	
5	years.4,5	Recurrent	 ischemic	stroke	 (IS)	has	been	associated	with	
increased	mortality	and	functional	dependence,6,7	but	this	remains	










2  | MATERIAL S AND METHODS
In	 this	 hospital‐based	 prospective	 cohort,	 all	 patients	 older	
than	 18	years	 admitted	with	 IS	 or	 TIA	 to	 the	 Stroke	Unit	 at	 the	
Department	 of	 Neurology,	 Haukeland	 University	 Hospital,	 be‐
tween	July	1,	2007,	and	December	31,	2013,	were	prospectively	
registered	 in	 the	 Bergen	 NORSTROKE	 Registry.	 Approximately	
275	000	people	 are	 living	 in	 the	 area	 served	by	our	 stroke	unit.	













infarctions	were	defined	as	MRI	 findings	of	 focal	 hyperintensity	
lesions	on	T2	sequences	and	low	signal	 intensity	in	the	presence	
of	 gliosis	 and/or	 cystic	 encephalomalacia	 on	 FLAIR	 sequences.9 
Differentiation	 from	 perivascular	 spaces	 and	 other	 lesions	 was	
made	by	a	neuroradiologist	or	experienced	stroke	clinician	 (HN).	




were	 classified	with	 the	Oxfordshire	 Community	 Stroke	 Project	




event.	 Clinical	 recurrence	 was	 identified	 by	 review	 of	 electronic	
medical	 records	 from	all	 ten	hospitals	under	 the	Western	Norway	
Regional	 Health	 Authority.	 Information	 on	 death	 was	 collected	
electronically	from	the	Norwegian	National	Registry.	Patients	were	
followed	until	 September	1,	2016.	Data	 collection	was	performed	
mainly	 during	 2017.	We	did	 not	 include	 intracerebral	 hemorrhage	







for	 continuous	variables.	Categorical	 variables	 are	presented	as	N	
(%),	and	continuous	variables	are	expressed	as	mean	±	standard	de‐




was	used	 to	estimate	 the	 incidence	of	 all‐cause	mortality.	Factors	
independently	associated	with	IS	or	TIA	recurrence	were	assessed	
with	backward	stepwise	Cox	regression	by	analysis	of	variables	that	















At	 index	 admission,	 714	 (38.1%)	 and	 158	 (8.4)	 patients	 were	
already	 on	 antiplatelet	 agents	 and	 anticoagulation	 agents,	 respec‐
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respectively.	At	index	discharge,	that	increased	to	1331	(71.1%),	1178	
(62.9%),	 and	 247	 (13.2%)	 patients.	 Only	 0.8%	 of	 patients	 (n	=	14)	
were	not	assigned	any	secondary	prevention,	mainly	because	of	con‐
traindications.	Cardioembolism	was	the	most	frequent	determined	






During	 a	mean	 follow‐up	 of	 5.6	years	 (median	 5.5	years,	 max.	
9.2	years,	 8172.8	 person‐years),	 220	 (11.7%)	 patients	 experienced	
241	(87%)	recurrent	IS	and	36	(13%)	TIA.	One	recurrent	event	was	
observed	 in	175	patients,	 two	 in	36	patients,	 three	 in	six	patients,	
and	 four	 in	 three	 patients.	 First	 recurrence	was	 IS	 in	 195	 (88.6%)	
patients	 and	 TIA	 in	 25	 (11.4%)	 patients.	Median	 time	 to	 the	 first	
recurrence	was	436.5	days.	Figure	1	demonstrates	 the	cumulative	
incidence	 function	 adjusted	 for	 age	 (CIF)	 of	 recurrent	 IS	 and	 TIA.	
The	total	cumulative	recurrence	rate	adjusted	for	age	during	follow‐
up	was	14.2%.	After	1	year	and	5	years,	 recurrence	was	observed	
in	 101	 (5.4%)	 and	 201	 (10.7%)	 patients,	 respectively,	 resulting	 in	





Baseline	 characteristics	 of	 the	 cohort	 stratified	 by	 recurrence	
status	at	the	end	of	follow‐up	are	presented	in	Table	1.	Patients	with	
recurrence	had	a	significantly	lower	discharge	mRS	score,	more	fre‐
quently	 a	 history	 of	 previous	 IS	 or	 TIA	 as	well	 as	 chronic	 infarcts	




from	 the	 final	 Cox	 regression	 model.	 History	 of	 hypertension	 at	
index	admission	was	 the	strongest	 independent	 risk	 factor,	with	a	









estimates	 representing	 the	 risk	of	 all‐cause	death	 after	 stroke	are	

















F I G U R E  1  Cumulative	incidence	of	first	recurrence	of	ischemic	stroke	or	TIA








were	 prescribed	 antiplatelet	 or	 anticoagulant	 treatment,	 and	 the	
use	of	 statins	 and	 antihypertensive	 treatment	was	high	 compared	
to	other	studies.14	Finally,	differences	in	populations,	methods,	and	




peting	 risk	of	death	have	reported	1‐	and	5‐year	 incidences	of	 re‐
currence	of	3.6%‐7.7%	and	10.1%‐16.8%.16‐19	Our	 results	 are	 thus	
supporting	newer	data	from	several	other	populations.
Among	 the	 factors	 associated	 with	 recurrence	 in	 our	 study,	
previous	 hypertension	 at	 index	 stroke	 was	 the	 strongest	 one.	
Hypertension	 is	 usually	 considered	 the	 single	most	 important	 risk	


















TA B L E  1  Baseline	characteristics	at	index	stroke	(N,	%)
 
No recurrence Recurrence
N = 1652 N = 220 P
Age	(y),	mean	±	SD 73.0	±	13.8 75.0	±	11.3 0.07








Ischemic	stroke 1468	(88.9) 198	(90.0) 0.61





Cardioembolism 537	(32.5) 67	(30.4) 0.54
Small	vessel	occlusion 187	(11.3) 18	(8.2) 0.16
Other	determined	etiology 27	(1.6) 5	(2.3) 0.49
Undetermined	etiology 694	(42.0) 93	(42.3) 0.94
OCSP	classification
TACI 164	(10.0) 15	(6.9) 0.15
PACI 771	(48.9) 111	(50.9) 0.26
POCI 322	(19.6) 46	(21.1) 0.60
LACI 388	(23.6) 46	(21.1) 0.42
Comorbidities	prior	to	index	event
Prior	ischemic	stroke 199	(12.1) 44	(20.0) <0.01
Prior	TIA 116	(7.0) 28	(12.7) <0.01
Peripheral	artery	disease 117	(7.1) 19	(8.6) 0.40
Coronary	artery	disease 367	(22.2) 51	(23.2) 0.75
Diabetes	mellitus 240	(14.5) 41	(18.6) 0.11
Atrial	fibrillation 476	(28.8) 67	(30.5) 0.61
Hypertension 902	(54.6) 150	(68.2) <0.01





Antiplatelet	agent 1069	(64.7) 159	(72.2) 0.03
Anticoagulation	agent 570	(34.5) 60	(27.3) 0.03








Antihypertensive	drugs 1025	(62.1) 153	(69.6) 0.03





TA B L E  2  Factors	associated	with	recurrence	after	IS	or	TIA,	
(n	=	1621)
 HR 95% CI P
Age,	y 1.02 1.00‐1.03 0.01
Female 0.99 0.74‐1.33 0.96
mRS	score 0.91 0.82‐1.01 0.07
History	of	IS	or	TIA 1.63 1.18‐2.24 <0.01




















tality	 are	not	well	 studied.	 Stroke	 severity	 is	 considered	 the	most	
significant	 factor	 influencing	 short‐	 and	 long‐term	 outcome	 after	















quality	 1‐	 and	5‐year	 recurrence	 and	mortality	 data	 in	 a	 hospital‐
based	 stroke	 population.	 A	 predefined	 investigation	 protocol	 and	
the	use	of	electronic	medical	records	for	identification	of	recurrent	
IS	or	TIA	provide	precise	and	accurate	 clinical	data	on	both	 index	
event	 and	on	 the	 recurrent	 episode	 as	 compared	 to	 studies	 using	
administrative	data.	All	ischemic	stroke	cases	were	confirmed	with	
imaging	studies.	On	this	background,	we	conclude	 that	 the	 risk	of	




CONFLIC T OF INTERE S T
None.
F I G U R E  2  Time	do	death	after	index	ischemic	stroke	or	TIA
TA B L E  3   Impact	of	recurrence	on	all‐cause	mortality	after	IS	or	
TIA,	(n	=	1854)
 HR 95% CI P
Recurrent	stroke 2.55 2.04‐3.18 <0.01
Age,	y 1.09 1.08‐1.10 <0.01
Female 0.85 0.72‐1.00 0.06
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